Literature DB >> 33308276

Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway.

Xiaomin Li1,2, Jiefeng He2, Xiaojing Ren2, Haichao Zhao2, Haoliang Zhao3.   

Abstract

BACKGROUND: The involvement of circular RNAs (circRNAs) in chemoresistance of tumors has been identified. Herein, this study aims to investigate the role and the underlying mechanism of circ_0003998 in doxorubicin (DOX) resistance in hepatocellular carcinoma (HCC).
METHODS: The expression of circ_0003998 and microRNA (miR)-218-5p and eukaryotic translation initiation factor 5A-2 (EIF5A2) mRNA was detected using quantitative real-time polymerase chain reaction. Cell viability, migration and invasion were analyzed using cell counting kit-8, colony formation and transwell assay, respectively. The levels of matrix metallopeptidase 9 (MMP-9), E-cadherin, Vimentin, N-cadherin and EIF5A2 protein were detected using western blot. The interaction between miR-218-5p and circ_0003998 or EIF5A2 was confirmed by dual-luciferase reporter assay. In vivo experiments were performed using murine xenograft models.
RESULTS: Circ_0003998 was elevated in HCC tissues, DOX-resistant tissues and cells, and circ_0003998 knockdown promoted DOX-sensitivity in HCC by inhibiting resistant cell viability, migration, invasion and EMT in vitro and enhanced DOX cytotoxicity in vivo. Bioinformatics analysis revealed circ_0003998 inhibited miR-218-5p expression, which was clarified to be a target of circ_0003998, and circ_0003998 knockdown sensitized HCC cell to DOX by sponging miR-218-5p. EIF5A2 was a target of miR-218-5p, and miR-218-5p mitigated DOX resistance in HCC cells through modulating EIF5A2 expression. Additionally, circ_0003998 served as a competing endogenous RNA for miR-218-5p to regulate EIF5A2 expression.
CONCLUSION: Circ_0003998 knockdown sensitized HCC cell to DOX by regulating miR-218-5p/EIF5A2 axis, indicating new markers of poor response to DOX and potential therapeutic strategies for the chemotherapy of HCC.

Entities:  

Keywords:  Doxorubicin resistance; EIF5A2; HCC; circ_0003998; miR-218-5p

Year:  2020        PMID: 33308276     DOI: 10.1186/s13000-020-01056-1

Source DB:  PubMed          Journal:  Diagn Pathol        ISSN: 1746-1596            Impact factor:   2.644


  4 in total

1.  eIF5A2 is an alternative pathway for cell proliferation in cetuximab-treated epithelial hepatocellular carcinoma.

Authors:  Fei Xue; Yanhui Liu; Haoyuan Chu; Yu Wen; Lei Yan; Qiang Tang; Erhui Xiao; Dongyi Zhang; Hongwei Zhang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

2.  MiR-183 modulates multi-drug resistance in hepatocellular cancer (HCC) cells via miR-183-IDH2/SOCS6-HIF-1α feedback loop.

Authors:  X-J Wang; D-L Zhang; C Fu; B-Z Wei; G-J Li
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016-05       Impact factor: 3.507

3.  Hepatocellular Carcinoma and High Grade Neuroendocrine Carcinoma: A Case Report and Review of the Literature.

Authors:  El Mehdi Tazi; Ismail Essadi; Hind M'rabti; Hassan Errihani
Journal:  World J Oncol       Date:  2011-02-26

4.  MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2.

Authors:  Fei Xue; Yuntian Liang; Zhenrong Li; Yanhui Liu; Hongwei Zhang; Yu Wen; Lei Yan; Qiang Tang; Erhui Xiao; Dongyi Zhang
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

  4 in total
  4 in total

Review 1.  Advances in the Study of CircRNAs in Tumor Drug Resistance.

Authors:  Song Wang; Long Qian; Tingting Cao; Li Xu; Yan Jin; Hao Hu; Qingsheng Fu; Qian Li; Ye Wang; Jiawei Wang; Yabin Xia; Xiaoxu Huang
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

Review 2.  The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.

Authors:  Sha Qin; Yitao Mao; Xue Chen; Juxiong Xiao; Yan Qin; Luqing Zhao
Journal:  Int J Biol Sci       Date:  2021-07-22       Impact factor: 6.580

Review 3.  Noncoding RNA-mediated molecular bases of chemotherapy resistance in hepatocellular carcinoma.

Authors:  Qikuan He; Pengyi Guo; Zhiyuan Bo; Haitao Yu; Jinhuan Yang; Yi Wang; Gang Chen
Journal:  Cancer Cell Int       Date:  2022-08-09       Impact factor: 6.429

Review 4.  Current Molecular Biology and Therapeutic Strategy Status and Prospects for circRNAs in HBV-Associated Hepatocellular Carcinoma.

Authors:  Rui Liao; Lei Liu; Jian Zhou; Xufu Wei; Ping Huang
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.